DNA Script Partners with Moderna to Develop On-Demand Vaccines and Therapeutics for DARPA
DNA Script announced a partnership with Moderna (MRNA) to develop a prototype for mobile vaccine and therapeutic manufacturing under DARPA's Nucleic Acids On-Demand World-Wide Program. This collaboration will utilize DNA Script's enzymatic synthesis platform to produce high-fidelity nucleic acids, enhancing Moderna's mRNA technology. DNA Script will receive up to $5 million in grant funding from DARPA. The initiative aims to create mobile units for rapid production of mRNA vaccines, potentially offering immediate medical responses to pathogen threats.
- Partnership with Moderna to enhance rapid mRNA vaccine production.
- Receives up to $5 million in funding from DARPA.
- Development of mobile manufacturing units for vaccines and therapeutics.
- None.
SOUTH SAN FRANCISCO, Calif. and PARIS, April 27, 2021 /PRNewswire/ -- DNA Script today announced a partnership with Moderna, Inc. (Nasdaq: MRNA) to develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the Defense Advanced Research Projects Agency's (DARPA) Nucleic Acids On-Demand World-Wide (NOW) Program. The partnership will employ DNA Script's novel enzymatic synthesis platform to quickly generate high-fidelity nucleic acids without the use of hazardous chemical solvents to power Moderna's existing manufacturing technology for the rapid production of messenger RNA therapeutics and vaccines. As part of the agreement, DNA Script will receive up to
DARPA's NOW initiative aims to develop a mobile, just-in-time manufacturing platform that quickly diagnoses pathogen threats and provides medical countermeasures to deliver pandemic prevention treatments. The resulting Good Manufacturing Practice (GMP-) quality nucleic acid (including mRNA) vaccines and therapeutics are intended to deliver near-instantaneous protections to both military personnel and local populations. The design envisions a manufacturing unit capable of producing hundreds of doses of medicines in a matter of days in a 6-foot x 6-foot x 6-foot (1.8m x 1.8m x 1.8m) container, deployable to remote locations around the world.
"We are thrilled to collaborate with Moderna and DARPA on this important initiative to create an innovative biotechnological approach to rapidly detect, characterize and mitigate threats from newly emerging or engineered pathogens," said Thomas Ybert, Chief Executive Officer of DNA Script. "We believe that our fast, efficient and intuitive SYNTAX™️ nucleic acid printer, underpinned by our proprietary Enzymatic DNA Synthesis technology, has the potential to help prevent future pandemics. We're proud to have been selected by both partners receiving awards under this DARPA NOW initiative."
About DNA Script
Founded in 2014 in Paris, DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science. The company is pioneering an alternative to traditional DNA synthesis called enzymatic DNA synthesis, or EDS, making this technology accessible to labs with the world's first benchtop enzymatic synthesis instrument, SYNTAX™️. By putting DNA synthesis back in the lab, DNA Script is transforming life science research through innovative technology that gives researchers unprecedented autonomy. www.dnascript.com
View original content:http://www.prnewswire.com/news-releases/dna-script-partners-with-moderna-to-develop-on-demand-vaccines-and-therapeutics-for-darpa-301277170.html
SOURCE DNA Script
FAQ
What is the partnership between MRNA and DNA Script about?
How much funding will DNA Script receive from DARPA?
What is the goal of the DARPA NOW Program?
What technology will be utilized in the MRNA partnership?
What are the expected outcomes of the mobile manufacturing units?
